Abstract Submission Deadline: July 18, 2025

Deadline:  All Abstracts are due electronically by July 18, 2025.

 

Suggested Guidelines for the Abstract Submission 

Provide information for each section listed below in the body of your abstract:

  • Title
  • Authors and organizational affiliations (with email for contact author)
  • Introduction and overall goal
  • Specific aims
  • Rationale and background
  • Methods and materials
  • Results
  • Discussion and conclusion
  • References (optional)

 

References Format

If there are citations, list references numerically at the end of the abstract in the order by which they were cited in the text.

Example: Cooperberg, MR, Broering, JM, Carroll PR, et. al. Time trends and local variation in primary treatment of localized prostate cancer, Journal of Clinical Oncology 2010 (28): 1117-1123.

 

Length, Font, and Format

The abstract should not exceed one page (single spaced). Use font no smaller than “Times New Roman 12” or “Arial 11”, and margins of at least 0.5 in.

 

General Content and Guidelines

  1. The content may not promote the proprietary interests of any commercial entity. Evident bias in favor of a particular product or company is grounds for rejection.
  2. Content must be restricted to pure science, technology, methodology, materials and/or operational characteristics of devices. Product and company names should be included only to identify the technology or methodology used, but not to promote proprietary interests.
  3. All research must conform to generally accepted standards of experimental design, data collection and analysis.
  4. The submitted abstract does not have to be an original submission and can be an encore abstract (i.e., it can have been submitted elsewhere)

 

Review Criteria

  1. Is this research novel?
  2. Does this research advance knowledge, and/or improve diagnostic information and/or capabilities?
  3. Does it produce new data or analysis of interest and relevance to the research or clinical community?
  4. Is the data substantive and not just implied? Does it describe a research accomplishment, rather than work yet to be done?
  5. Is comprehensive statistical analysis relevant and applied?
  6. Are recommendations involving clinical medicine based on evidence that is accepted as adequate justification for indications and contraindications in patient care?
  7. What is the impact factor of this work? The abstract should address how the proposed study is expected to impact research or patient care.
  8. Is the abstract biased in favor of a particular product or company? Evident bias is grounds for rejection. (Use of a particular company’s products or equipment does not represent bias. Non-data- based statements of comparative superiority, however, would be considered biased.)

 

Abstract Publication, Competition and Presentation

If your abstract is selected, it will be published electronically on the dedicated Summit 2025 website pages of the AdMeTech Foundation.

All abstracts will undergo a peer review, will be scored and take part in a competition. The authors of the top three abstracts will have an opportunity to have presentations of their work (3 minutes each) during the main scientific program on Wednesday, September 17, 2025.

Winners of the top three abstracts will be announced on the dedicated AdMeTech Foundation’s website pages, social media and dedicated newsletters. They will also receive free registrations for Summit 2026.

 

Videos for Winning Abstracts

You will be required to provide a 3-minute video of your presentation by August 11, 2025, preferably in a mp4. format, to Emma Couillard by email at emma.couillard@admetechfoundation.org.  Prior to its submission, please upload your video into Google Drive and then share it as the editable file with the above listed email address. This way, your video can be downloaded and professionally edited, if needed. If you need any assistance with or questions about preparing your video, please contact Emma Couillard by email as above.

 

Failure to Present

Submission of an abstract is considered a commitment to present the poster during main scientific program, if it is accepted and wins one of the top three places. Failure to present a poster may jeopardize future submissions by the same author.

 

Submission

Please send abstract in a PDF format to faina.n.shtern@admetechfoundation.org, with the Subject Line “2025 Summit Abstract” by July 18, 2025.

 

Registration is Required Prior to Review of Your Abstract

When you submit your abstract, you will be provided access to a discounted (50%) registration fee. Your registration is required prior to review of your abstract.

If you are experiencing financial hardship, please request free access to the event.

For assistance with the offered 50% discounted or free registrations in connection with the abstract submissions, please contact Emma Couillard by email at emma.couillard@admetechfoundation.org.

ABSTRACT REVIEW COMMITTEE

Peter Albers, MD

Chairman, Department of Urology, Medical Faculty, Heinrich-Heine-University Düsseldorf and Division Head, Division of Personalized Early Detection of Prostate Cancer at the German Cancer Research Center (DKFZ) Heidelberg, Germany

Paul Boutros, PhD, MBA

Director of Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, UCLA

E. David Crawford, MD

Professor of Urology, University of California San Diego; Chairman, Prostate Conditions Education Council; Editor in Chief, Grand Rounds in Urology; and Prostate Cancer Series Editor, Oncology Journal

Andrei H. Iagaru, MD, FACNM

Bio

Andrei Iagaru, MD, FACNM

Professor of Radiology – Nuclear Medicine Chief, Division of Nuclear Medicine and Molecular Imaging; and Co-Director, PET-MRI Research Program Stanford University

Daniel Margolis, MD

Associate Professor of Radiology, Director, Prostate MRI, and Chair, Weill Cornell Institutional Review Board, Weill Cornell Medical College, Cornell University

Steven Raman, MD

Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of Medicine, UCLA

Daniel Y. Song, MD

Professor of Radiation Oncology and Molecular Radiation Sciences, and Co-Director, Prostate Cancer Multi-Disciplinary Clinic, Johns Hopkins University

Timothy Sotman, MD

Assistant Professor of Diagnostic Radiology, Oregon Health and Science University

Preston Sprenkle, MD

Assistant Professor of Surgery, Yale University School of Medicine; and Member, NCCN Prostate Cancer Early Detection Panel

Sandy Srinivas, MD

Medical Oncologist, Stanford Health Care; Professor of Medicine (Oncology) and Urology, Stanford University; and Vice Chair, NCCN Panel for Prostate Cancer Treatment